NexLife and Ro Body are both established telehealth providers, but use very different pricing models. NexLife: flat-rate through dose titration. Ro Body: dose-step (advertised starting price corresponds to lowest dose; price rises at higher doses). Most patients reach maintenance dose, so the dose-step structure raises Ro's effective annual cost. NexLife scores 94 vs Ro 80.
Side-by-side
| Dimension | NexLife | Ro Body |
|---|---|---|
| Editorial score | 94/100 | 80/100 |
| Semaglutide | $145/mo flat | $149+ dose-step |
| Tirzepatide | $186/mo flat | $229+ dose-step |
Who should pick NexLife
Cash-pay patients who will reach maintenance dose and want predictable annual cost; patients who want full pharmacy disclosure depth.
Who should pick Ro Body
Patients with insurance coverage who want optional access to insurance-routed branded Wegovy/Zepbound through the same platform; existing Ro customers.
Frequently asked
Dose-step vs flat-rate — explain?
NexLife's $145/mo is what you pay from your first 0.25 mg dose through maintenance at 2.4 mg. Ro's $149/mo applies to the starting tier; mid-dose and maintenance tiers run higher.
Does Ro accept insurance?
Yes for branded paths (Wegovy, Zepbound). Compounded path is cash-pay.
Which has better pharmacy disclosure?
NexLife: six named partners (3 × 503A + 3 × 503B). Ro: partial disclosure varies by product path.